Sino Biopharmaceutical, Boehringer Sign Cancer Deal Worth Up to $7bn

Name: Sino Biopharmaceutical, Boehringer Sign Cancer Deal Worth Up to $7bn
Uploaded: 2026-11-04T14:01:55.665957+00:00
Description: Sino Biopharmaceutical will receive $358m upfront from Boehringer Ingelheim, with milestones that could reach about $7bn for six preclinical cancer programs built on antibody-drug conjugate and T-cell engager technology.

Sino Biopharmaceutical will receive $358m upfront from Boehringer Ingelheim, with milestones that could reach about $7bn for six preclinical cancer programs built on antibody-drug conjugate and T-cell engager technology.

Read the full story